Introduction: Nicotine withdrawal symptoms are important factors in determining the relapse rate to tobacco smoking and drugs that diminish these symptoms would potentially have a higher success rate as smoking cessation aids. Unlike US Food and Drug administration approved smoke cessation aids (nicotine and varenicline) which act as nicotinic acetylcholine receptors (nAChRs) agonists, desformylflustrabromine (dFBr) acts as a nAChR positive allosteric modulator with higher selectivity to the α4β2 nAChR. In animal studies, dFBr was well tolerated and reduced intravenous nicotine self-administration. In this study, we use behavioral test in mouse model of spontaneous nicotine withdrawal to assess the effect of dFBr on nicotine withdrawal symptoms. Methods: Spontaneous nicotine withdrawal in nicotine-dependent ICR male mice was established 18-24 h after termination (minipump removal) of 14 days infusion of nicotine. After that (day 15), spontaneous signs of nicotine withdrawal were examined in the following order: anxiety-like behaviors, somatic signs, and then hyperalgesia using previously published behavioral protocols. Fifteen minutes before withdrawal signs testing, mice received a subcutaneous acute injection of vehicle or dFBr at the doses of 0.02, 0.1, and 1 mg/kg to determine the effect of dFBr on nicotine withdrawal symptoms. Results: dFBr produced dose-dependent reversal of nicotine withdrawal signs in mouse model of spontaneous nicotine withdrawal. Implications: Positive allosteric modulators of nAChR such as dFBr reduce nicotine withdrawal symptoms supporting the potential clinical use of this novel class of nAChR-based therapeutics as smoking cessation aid.
Introduction
Tobacco smoking raises the risk of cancer, cardiovascular, and pulmonary diseases and contributes to several other preventable diseases and disabilities. While tobacco smoke contains hundreds of chemicals, nicotine is the main active ingredient in tobacco smoke that leads to and maintains tobacco addiction. 1 Nicotine acts on nicotinic acetylcholine receptors (nAChRs) expressed within the brain reward pathways including dopaminergic, GABAergic, and glutamatergic neurons that project from or to the ventral tegmental area (VTA). 2 Activation of nAChRs, especially the α4β2* subtype, increases the firing rate of VTA dopaminergic neurons and increases dopamine level in the nucleus accumbens which is believed to mediate the rewarding effects associated with tobacco smoking. [3] [4] [5] Upon continuous use of tobacco products and sustained brain exposure to nicotine, dependence develops and smokers find it too difficult to quit even with the help of smoking cessation aids. 6 However, currently available smoking cessation aids such as nAChR agonists (nicotine replacement therapy and varenicline) are modestly efficacious and associated with side effects. Therefore, more effective and safer pharmacological interventions for smoking cessation are still needed. To this end, there are increasing efforts to develop positive allosteric modulators (PAMs) that are selective for the α4β2* nAChR subtype for treatment of nicotine dependence and neurological disorders. 7, 8 Unlike agonists, nAChR PAMs do not directly activate nAChRs; instead they enhance nAChR responses to the endogenously released ACh. As such, nAChR PAMs represent a more physiological alternative to classical nAChR agonists and potentially have higher nAChR subtype selectivity. 9 To date, a number of nAChR PAMs with higher selectivity to the α4β2 nAChRs, the primary nAChRs subtype mediating the addictive properties of nicotine, have been identified including desformylflustrabromine (dFBr). dFBr is a naturally occurring alkaloid that first isolated from Flustra foliacea then synthesized and its effect on nAChRs was demonstrated.
10,11 dFBr enhances AChinduced responses of α4β2 nAChRs increasing ACh efficacy at the two known isoforms of α4β2 nAChRs [(α4)3(β2)2 and (α4)2(β2)3 nAChRs]. [11] [12] [13] Furthermore, dFBr has been shown to reduce intravenous nicotine self-administration in rats and to modify the discriminative stimulus effects of nicotine. 14, 15 Withdrawal symptoms are one of the primary causes of high tobacco smoking relapse rates, 16 and it is important to test the effects of potential nicotine dependence pharmacotherapies on nicotine withdrawal symptoms. Because the α4β2* nAChRs play an important role in nicotine withdrawal, we hypothesized that α4β2 PAMs like dFBr, would reverse withdrawal signs. To this end, in this study we examined the effect of acute dFBr administration in a well-established mouse model of nicotine withdrawal. Our results demonstrate that dFBr reverses important aspects of nicotine withdrawal extending in vivo characterization of dFBr as a potential drug for the treatment of nicotine addiction.
Methods

Subjects
All animal experiments described in this study were conducted on adult (20-25 g; 8-10 weeks old) male ICR mice using protocols approved by the Institutional Animal Care and Use Committee of Virginia Commonwealth University. ICR mice were purchased from Harlan Laboratories (Indianapolis, IN) and housed in groups of five with free access to food and water in an Association for Assessment and Accreditation of Laboratory Animal Care approved facility. Mice received corn cob bedding and were fed Envigo Teklad mouse diet 7102 (LM-485) and were kept at 12 light/12 dark cycle and behavioral experiments were performed during the light cycle.
Drugs
(−)-Nicotine hydrogen tartrate salt [(−)-1-Methyl-2-(3-pyridyl) pyrrolidine (+)-bitartrate salt], was purchased from Sigma-Aldrich (St. Louis, MO). dFBr was obtained from Tocris Biosciences (Minneapolis, MN). All drugs were dissolved in physiological saline (0.9% sodium chloride) to the required doses expressed as the free base of the drug. dFBr at doses 0.02, 0.1, and 1 mg/kg body weight were injected subcutaneously (s.c.) in a total volume of 1 mL/100 g body weight.
Chronic Administration of Nicotine
Subcutaneous Alzet osmotic minipumps [(model 2002); Durect Corporation, Cupertino, CA] were used to achieve continuous nicotine administration to ICR mice. Nicotine and saline minipumps were implanted in mice under anesthesia (45 mg/kg sodium pentobarbital, i.p.) and kept at a constant flow rate to deliver 24 mg nicotine/kg animal body weight/day for 14 days.
Behavioral Assessment of Nicotine Withdrawal
Following 14 days minipump infusion of 24 mg nicotine/kg animal body weight/day, minipumps were removed from mice (in the evening of day 14) and behavioral observation were performed on day 15, 18-24 h after minipump removal. Mice were pretreated 15 min before behavioral observations with either vehicle or dFBr (0.02, 0.1, and 1 mg/kg; s.c.) to assess the effects of acute dFBr administration on spontaneous withdrawal from nicotine. Behavioral test were performed by an observer blinded to experimental treatment and in specific testing sequence known to produce the most consistent results with minimal within-group variability. 17 The mice were first evaluated for 5 min in the plus maze test for anxiety-related behavior, followed by a 20-min observation of somatic signs measured as paw and body tremors, head shakes, backing, jumps, curls, and ptosis. Hyperalgesia was evaluated in the hot-plate test (52°C) immediately following the somatic sign observation period as previously desscribed. 17 
Data Analysis
All behavioral data analyses were performed using the GraphPad software, version 6.0 (GraphPad Software, Inc., La Jolla, CA). Data were expressed as the mean ± SEM and assessed for the normality of the residuals and equal variance using either the F-test or the Brown-Forsythe test and the Bartlett's test before statistical analyses. All data passed these tests as indicated by similar Variances among groups. Statistical analyses included a one-way analysis of variance (ANOVA) followed by the Tukey post hoc correction with p-values <.05 considered significant.
Results
Anxiety-Related Signs of Nicotine Withdrawal
Anxiety-related behavior signs were measured in mice following 18-24 h withdrawal from 14 days infusion of nicotine (24 mg/kg/ day) or saline and following acute treatment with dFBr or vehicle. Consistent with previous reports, 18 nicotine withdrawal (nicotine minipump) mice demonstrated a significant (p < .05) increase in anxiety-related behavior in the plus maze (assessed as a decrease in time spent in the open arms) compared to control (saline minipump) mice ( Figure 1A) . Acute s.c. administration of 1 mg/kg dFBr or vehicle to saline minipump (nicotine naïve) mice did not significantly (p > .05) alter anxiety-related behavior indicating that dFBr does not induce anxiety-related behavior in the absence of nicotine. In contrast, acute s.c. administration of 0.02, 0.1, and 1 mg/kg dFBr to nicotine minipump mice (nicotine withdrawal group) produced a dose-dependent reversal of anxiety-related behavior ( Figure 1A ). One way ANOVA followed by Tukey post hoc revealed that dFBr at 1 mg/kg significantly (F 5,42 = 9.837, p < .0001) reverse nicotine withdrawal anxiety-related behavior. Analyses of the average total number of arm crosses for each treatment group revealed no significant difference among groups (Table 1) indicating that the observed reductions in time mice spent in the open arms of the plus maze were not related to changes in mice locomotor activity.
Somatic Signs of Nicotine Withdrawal
The effects of dFBr administration on somatic signs of spontaneous nicotine withdrawal were assessed using same nicotine withdrawal (nicotine minipumps) and control (saline minipumps) mice described above. Following pretreatment with dFBr or vehicle and plus maze test, somatic signs (paw and body tremors, head shakes, backing, jumps, curls, and ptosis) were observed for 20 min. Nicotine minipumps mice developed somatic signs ( Figure 1B ), indicated by a significant (p < .05) increase in number of observations compared to the control (saline minipumps) mice. Similar to anxiety-related behavior, acute s.c. administration of the highest dose of dFBr did not alter somatic signs in the control (saline minipump) mice (p > .05) whereas dFBr pretreatment produce dose-dependent reversal of somatic signs in nicotine minipump mice ( Figure 1B ). One way ANOVA followed by Tukey post hoc revealed significant (F 5,42 = 86.34, p < .0001) dFBr effect at both 0.1 and 1 mg/kg.
Hyperalgesia Signs of Nicotine Withdrawal
Following testing anxiety-related and somatic signs of nicotine withdrawal, same mice groups (nicotine or saline minipumps then acute dFBr or vehicle pretreatment) were evaluated for hyperalgesia using the hot-plate test ( Figure 1C ). Withdrawal from chronic nicotine exposure (nicotine minipump mice) resulted in significant (p < .05) decrease in hot plate latency (hyperalgesia) compared to saline minipump mice. While s.c. of 1 mg/kg dFBr with produced no change in hot plate latency in saline minipump mice, s.c. injection of 0.02 or 0.1 mg/kg dFBr in nicotine minipump mice produced, respectively, ~50 and ~100% reversal in nicotine withdrawal induced reduction in hot plate latency ( Figure 1C) . One-way ANOVA followed by Tukey post hoc revealed that the effect of 0.1 mg/kg dFBr on nicotine withdrawal induced hyperalgesia was (F 5,42 = 4.325, p = .0029).
Discussion
Our results showed that dFBr, an α4β2 PAM, reversed withdrawal signs in mice undergoing spontaneous withdrawal after chronic nicotine infusion. The majority of high-affinity nicotine binding sites in the brain are associated with the α4β2* nAChR subtype. 19 Mice lacking the α4β2* nAChR (eg, β2 knock-out mice) lack the majority of nicotine binding sites; do not self-administer nicotine; and exhibit minimal VTA dopaminergic activity in response to exogenously administered nicotine. 3, 4 They also exhibit a loss of anxiety-related behavior and a loss of aversion in spontaneous and conditioned place aversion nicotine withdrawal models indicating that β2 containing nAChRs are involved in the affective signs of nicotine withdrawal. 17 Therefore, PAMs of α4β2 nAChR such as dFBr represent an emerging class of nAChR-based therapeutics for nicotine dependence. They potentially provide selective modulation of α4β2 nAChR subtype while avoiding side effects seen with nAChR agonists due to binding at multiple nAChR subtypes. In addition, dFBr has been shown to replace nicotine in rat model without exerting reinforcing actions of its own suggesting that dFBr reduces the need for tobacco intake with minimal abuse liability.
14 Nicotine withdrawal symptoms include intense cravings for tobacco smoking and a profound state of dissatisfaction, anxiety, irritability, insomnia, and depression. These symptoms begin within days after nicotine abstention and can continues for months and are considered one of the primary causes of high tobacco smoking relapse rates. 16 Diminishing the dysphoric-like state associated with nicotine withdrawal is believed to prevent relapse to tobacco use and has been shown to contribute to the effect of varenicline and cytisine as smoking cessation aids. 20 In this study, we evaluated the effects of dFBr, a nAChR PAM with apparent selectivity to the α4β2 nAChR subtype, on nicotine withdrawal symptoms in mice.
As previously published, 18 nicotine withdrawal significantly increased anxiety-related behaviors, increased expression of somatic withdrawal signs, and decreased response latencies in the hotplate test. Acute administration of dFBr 18-24 h following reversed, in a dose dependent manner, anxiety-related behavior and somatic signs of nicotine withdrawal with >90% of these signs reversed at 1 mg/kg dFBr. Furthermore, dFBr was even more potent in alleviating nicotine withdrawal induced hyperalgesia where almost full reversal obtained at 0.1 mg/kg dFBr. These dFBr effects were specific to in chronically nicotine-exposed mice as dFBr at equal doses produced little effect, if any, in a parallel control (saline minipump) mice group. Also, dFBr effects were specific to nicotine withdrawal anxiety-related behaviors and did not alter mice locomotor activities as measured by the number of crosses in the plus maze. Altogether, these results establish that dFBr alleviated important aspects of spontaneous withdrawal signs in chronically nicotine-exposed but not naïve mice. These findings, to the best of our knowledge, the first in vivo experimental results to support a role of an α4β2 nAChR PAM in diminishing dystrophic-like state and hyperalgesia associated with nicotine withdrawal.
Conclusion
The low success rate, the high prevalence of side effects, and the high relapse rates associated with current smoking cessation aids demand the development of more selective and safer medication for the management of nicotine dependence. One emerging strategy is the use of nAChR PAMs which potentially have more favorable pharmacological profiles than currently used nAChR agonists. Because drugs that diminish nicotine withdrawal symptoms will more likely to have a lower tobacco smoking relapse rates, in this study we sought to provide in vivo evidence that nAChR PAMs such as dFBr have this desirable effect. Our results show that dFBr diminish affective behavior associated with nicotine withdrawal supporting a promising role of α4β2 nAChR PAM as a pharmacological strategy for tobacco smoking cessation aid.
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